Science & Technology-R&D Result

Providing innovative and affordable medicines

for all patients

Zhu, X., Ding, Y., Wang, Q. et al. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial. Invest New Drugs (2023). https://doi.org/10.1007/s10637-023-01338-7

Publications

Poster: Shi, Y.; Zhang, Q.; Han, X.; Song, Y.; Qin, Y.; Hong, X.; Ke, X.; Feng, J.; Wang, D.; Li, W.; Su, H.; Zhang, Y.; Zhang, H.; Yang, J.; Liu, L.; Zhang, X.; Liu, E.; Jiang, W.; Liu, S.; Luk, A., 286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology 2018, 29 (suppl_9), mdy437.005-mdy437.005.
ESMO-ASIA 2018
Poster: Xu, B.; Zhang, Q.; Sun, T.; Li, W.; Teng, Y.; Hu, X.; Bondarenko, I.; Adamchuk, H.; Li, Y.; Shan, B.; Cheng, J.; Peng, T.; Wang, X.; Chen, Y.; Jiang, W.; Liu, S.; Zhang, X.; Liu, E.; Luk, A.; Wang, Q., LBA6First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer. Annals of Oncology 2019, 30 (suppl_9), mdy446.005.

ESMO-ASIA 2018

Intellectual Property

Relevant Products	Patent Name	Patent Holder	Patent Number	Jurisdiction of Registration	Application Date	Expiry Date	Type
Platform Technology	Kit for detecting DNA residues of CHO cell and using method thereof	Henlius	ZL201110066745.4	Chinese mainland	2011-03-18	2031-03-18	Invention
Platform Technology	Method for detecting DNA content of CHO cells by probe	Henlius	ZL201110099204.1	Chinese mainland	2011-04-20	2031-04-20	Invention
Platform Technology	Eukaryotic expression vector and system for producing recombinant protein by using CHO cells	Henlius	ZL201210211812.1	Chinese mainland	2012-06-25	2032-06-25	Invention
HLX07	Anti-epidermal growth factor receptor (EGFR) antibodies	Henlius	ZL201580029644.6 HK1252789 J/4492 TWI689520 US10584171 AU2015266664 JP6691872 EP3148581 EP3613433 KR102366644 US11261255	Chinese mainland Hong Kong China Macao China Taiwan China The United States Australia Japan UK, GER, FR, ITA, ESP UK, GER, FR, ITA, ESP Korea The United States	2015-05-29	2035-05-29 2035-12-11	Invention
HLX10	Anti-programmed cell death protein 1 monoclonal antibody injection Anti-PD-1 antibodies	Henlius	ZL202010008058.6 HK40018285 ZA201901865 US11028173 RU2752832 JP7072576 ZL201780056868.5 TWI772326 KR102391338 IDP000083833	Chinese mainland Hong Kong China The United States South Africa Russia Japan Chinese mainland Taiwan China Korea Indonesia	2020-01-06 2017-09-09	2040-01-06 2037-09-08 2037-09-09 2037-09-09 2037-09-15 2037-09-09 2037-09-09	Invention
HLX53	AntiI-TIGIT antibodies and methods of use	Henlius	ZL202010024565.9 HK40013828	Chinese mainland Hong Kong China	2020-01-10	2040-01-10	Invention
Platform Technology	Online system for monitoring yield and quality of target protein	Henlius	ZL202020160862.1	Chinese mainland	2020-02-11	2030-02-10	Utility Model
Platform Technology	Online quantitative detection system for target protein	Henlius	ZL202020432845.9	Chinese mainland	2020-03-30	2030-03-29	Utility Model

304am永利集团|·主頁(歡迎您)